Circulating PCSK9 levels and conventional risk factors in CAD
Article Sidebar
-
Coronary Artery Disease, Apo B, PCSK9, Conventional Risk factors
Abstract
Coronary artery disease (CAD) is the chief cause of mortality and morbidity worldwide. The aim of this study was to compare the levels PCSK9 and conventional risk factors of CAD in CAD patients and age and sex-matched controls and also to evaluate the relationship of circulating PCSK9 levels with other conventional risk factors of coronary artery patients. Sixty two clinically proved CAD patients and sixty-two healthy; age and sex-matched subjects without CAD were selected for the study. Detailed clinical and other relevant data were recorded using proforma. Five ml of fasting venous blood was collected from all the subjects and used for the investigations of fasting plasma glucose (FPG), HBA1C, total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol (Direct), Apo B and PCSK9. The outcomes of this study showed that levels of FPG, HbA1c, lipid parameters-total cholesterol, triglycerides, LDL-c, Apo B were significantly higher whereas HDL-c were significantly low in CAD patients compared to normal controls. Circulating PCSK9 level was significantly elevated, and its level was correlated with other risk parameters. This study found that circulating PCSK9 level was significantly high, and its level was correlated with other risk parameters.
Full text article
References
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., Derré, A., Villéger, L., Farnier, M., Beucler, I., Bruckert, E., Chambaz, J., Chanu, B., Lecerf, J.-M., Luc, G., Moulin, P., Weissenbach, J., Prat, A., Krempf, M., Junien, C., Seidah, N. G., Boileau, C. 2003. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nature Genetics, 34(2):154–156.
Bae, K. H., Kim, S. W., Choi, Y. K., Seo, J. B., Kim, N., Kim, C. Y., Lee, W. K., Lee, S., Kim, J. G., Lee, I. K., Lee, J. H., Park, K. G. 2018. Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome. Diabetes & Metabolism Journal, 42(3):207–214.
Calder, P. C. 2012. The role of marine omega-3 ( n -3) fatty acids in inflammatory processes, atherosclerosis and plaque stability. Molecular Nutrition & Food Research, 56(7):1073–1080.
Cariou, B., Guérin, P., May, C. L., Letocart, V., Arnaud, L., Guyomarch, B., Pichelin, M., Probst, V. 2017. Circulating PCSK9 levels in acute coronary syndrome: Results from the PC-SCA-9 prospective study. Diabetes & Metabolism, 43(6):529–535.
Caselli, C., Turco, S. D., Ragusa, R., Lorenzoni, V., Graaf, M. D., Basta, G., Scholte, A., Caterina, R. D., Neglia, D. 2019. Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina. Cardiovascular Diabetology, 18(1).
Chaudhary, R., Garg, J., Shah, N., Sumner, A. 2017. PCSK9 inhibitors: A new era of lipid lowering therapy. World Journal of Cardiology, 9(2):76.
Chernogubova, E., Strawbridge, R., Mahdessian, H., Mälarstig, A., Krapivner, S., Gigante, B., Hellénius, M. L., Faire, U. D., Franco-Cereceda, A., Syvänen, A. C., Troutt, J. S., Konrad, R. J., Eriksson, P., Hamsten, A., Hooft, F. M. 2012. Common and Low- Frequency Genetic Variants in the PCSK9 Locus Influence Circulating PCSK9 Levels. Arteriosclerosis, Thrombosis, and Vascular Biology, 32(6):1526– 1534.
Cui, Q., Ju, X., Yang, T., Zhang, M., Tang, W., Chen, Q., Hu, Y., Haas, J. V., Troutt, J. S., Pickard, R. T., Darling, R., Konrad, R. J., Zhou, H., Cao, G. 2010. Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. Atherosclerosis, 213(2):632–636.
Delles, C., Dymott, J. A., Neisius, U., Rocchiccioli, J. P., Bryce, G. J., Moreno, M. U., Carty, D. M., Berg, G. A., Hamilton, C. A., Dominiczak, A. F. 2003. Reduced LDL-cholesterol levels in patients with coronary artery disease are paralelled by improved endothelial function: An observational study in patients from. Atherosclerosis, 211(1):271–277.
Desforges, J. F., Gordon, D. J., Rifkind, B. M. 1989. High-Density Lipoprotein — The Clinical Implications of Recent Studies. New England Journal of Medicine, 321(19):1311–1316.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 2001. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA: The Journal of the American Medical Association, 285(19):2486– 2497.
Harchaoui, K., Visser, M., Kastelein, J., Stroes, E., Dallinga-Thie, G. 2009. Triglycerides and Cardiovascular Risk. Current Cardiology Reviews, 5(3):216–222.
Hwang, H. S., Kim, J. S., Kim, Y. G., Lee, S. Y., Ahn, S. Y., Lee, H. J., Lee, D. Y., Lee, S. H., Moon, J. Y., Jeong, K. H. 2020. Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients. Journal of Clinical Medicine, 9(1).
Kim, J. S., Kim, W., Woo, J. S., Lee, T. W., Ihm, C. G., Kim, Y. G., Moon, J. Y., Lee, S. H., Jeong, M. H., Jeong, K. H. 2016. The Predictive Role of Serum Triglyceride to High-Density Lipoprotein Cholesterol Ratio According to Renal Function in Patients with Acute Myocardial Infarction. PLOS ONE, 11(10).
Krishnan, M. N. 2012. Coronary heart disease and risk factors in India - On the brink of an epidemic? Indian Heart Journal, 64(4):364–367.
Lambert, G., Sjouke, B., Choque, B., Kastelein, J. J., Hovingh, G. K. 2012. The PCSK9 decade. Journal of Lipid Research, 53(12):2515–2524.
Li, S., Guo, Y. L., Xu, R. X., Zhang, Y., Zhu, C. G., Sun, J., Qing, P., Wu, N. Q., Jiang, L. X., Li, J. J. 2014. Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease. Atherosclerosis, 234(2):441– 445.
Mack, M., Gopal, A. 2016. Epidemiology, Traditional and Novel Risk Factors in Coronary Artery Disease. Heart Failure Clinics, 12(1):1–10.
Mashayekhi, N. R., Sadrnia, S., Chehrei, A., Javaheri, J. 2014. The correlation between serum ApoA1 and B and coronary artery disease as well as its severity. International cardiovascular research journal, 8(1).
Moebus, S., Stang, A., Möhlenkamp, S., Dragano, N., Schmermund, A., Slomiany, U., Hoffmann, B., Bauer, M., Broecker-Preuss, M., Mann, K., Siegrist, J., Erbel, R., Jöckel, K. H. 2009. Association of impaired fasting glucose and coronary artery calcification as a marker of subclinical atherosclerosis in a population-based cohort—results of the Heinz Nixdorf Recall Study. Diabetologia, 52(1):81–89.
Nose, D., Shiga, Y., Ueda, Y., Idemoto, Y., Tashiro, K., Suematsu, Y., Kuwano, T., Kitajima, K., Saku, K., ichiro Miura, S. 2019. Association between plasma levels of PCSK9 and the presence of coronary artery disease in Japanese. Heart and Vessels, 34(1):19–28.
Pott, J., Schlegel, V., Teren, A., Horn, K., Kirsten, H., Bluecher, C., Kratzsch, J., Loeffler, M., Thiery, J., Burkhardt, R., Scholz, M. 2018. Genetic Regulation of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Plasma Levels and Its Impact on Atherosclerotic Vascular Disease Phenotypes. Circulation: Genomic and Precision Medicine, 11(5).
Rajagopal, G., Suresh, V., Sachan, A. 2012. High- density lipoprotein cholesterol: How High. Indian journal of endocrinology and metabolism, 16(2).
Riwanto, M., Rohrer, L., Roschitzki, B., Besler, C., Mocharla, P., Mueller, M., Perisa, D., Heinrich, K., Altwegg, L., von Eckardstein, A., Lüscher, T. F., Landmesser, U. 2013. Altered Activation of Endothelial Anti- and Proapoptotic Pathways by High-Density Lipoprotein from Patients with Coronary Artery Disease. Circulation, 127(8):891– 904.
Sahebkar, A., Simental-Mendía, L. E., Guerrero Romero, F., Golledge, J., Watts, G. F. 2015. Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials. Diabetes, Obesity and Metabolism, 17(11):1042– 1055.
Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., Chretien, M. 2003. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation. Proceedings of the National Academy of Sciences, 100(3):928–933.
Sherwani, S. I., Khan, H. A., Ekhzaimy, A., Masood, A., Sakharkar, M. K. 2016. Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. Biomarker Insights, 11:BMI.S38440.
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Merz, C. N. B., Blum, C. B., Eckel, R. H., Mcbride, P. 2014. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 63(25):2889– 2934.
Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.